therapy

1:12
Where is ovarian cancer treatment headed?
Domenica Lorusso
2:14
New potential applications for CAR T-cell therapy
Howard Burris
5:54
PROSPECT: how effective is the new prostvac vaccine against prostate cancer?
James Gulley
3:22
Drugs with low response rates – should they always be offered to patients?
Jacob Kettle
1:54
Proton beam therapy in the UK: usage and monitoring
Anthony Zietman
0:34
Key messages on prostate cancer treatment from BOPA 2017
Robert Jones
3:04
Improving radiation treatment using proton beam therapy
Anthony Zietman
5:53
Proton beam therapy for non-pediatric cancers: UK vs. US
Anthony Zietman
1:53
PARP inhibitors: game-changers for ovarian cancer patients?
Mansoor Mirza et al.
1:44
The delivery of niraparib and rucaparib as ovarian cancer treatment options
Mansoor Mirza
0:50
ESMO’s scientific value for gynecologic oncology
Mansoor Mirza et al.
0:48
Rituximab and its biosimilars: consistencies and advantages
Wojciech Jurczak
1:36
Trabectedin and pazopanib: an indirect comparison of their ability to treat LMS
Robin Jones
3:01
Managing the side effects of immunotherapy: a vital consideration
Paolo Ascierto
1:05
Critical data points in the production of biosimilars
Richard Markus
0:32
What can biosimilars offer us?
Richard Markus
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals